HK1220397A1 - 用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物 - Google Patents

用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物

Info

Publication number
HK1220397A1
HK1220397A1 HK16108574.9A HK16108574A HK1220397A1 HK 1220397 A1 HK1220397 A1 HK 1220397A1 HK 16108574 A HK16108574 A HK 16108574A HK 1220397 A1 HK1220397 A1 HK 1220397A1
Authority
HK
Hong Kong
Prior art keywords
rnai
polyconjugates
delivery
tumor cells
vivo
Prior art date
Application number
HK16108574.9A
Other languages
English (en)
Inventor
承為軍
‧黃
‧埃爾米達
‧羅澤瑪
‧布羅金
‧卡爾森
Original Assignee
Arrowhead Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Res Corp filed Critical Arrowhead Res Corp
Publication of HK1220397A1 publication Critical patent/HK1220397A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
HK16108574.9A 2013-08-07 2016-07-19 用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物 HK1220397A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361863056P 2013-08-07 2013-08-07
PCT/US2014/049851 WO2015021092A1 (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Publications (1)

Publication Number Publication Date
HK1220397A1 true HK1220397A1 (zh) 2017-05-05

Family

ID=52449177

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108574.9A HK1220397A1 (zh) 2013-08-07 2016-07-19 用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物

Country Status (14)

Country Link
US (3) US9487556B2 (zh)
EP (1) EP3030244B1 (zh)
JP (1) JP6433001B2 (zh)
KR (1) KR20160035081A (zh)
CN (1) CN105451743B (zh)
AU (1) AU2014306021B2 (zh)
CA (1) CA2919088A1 (zh)
EA (1) EA201690051A1 (zh)
HK (1) HK1220397A1 (zh)
IL (1) IL243941B (zh)
MX (1) MX2016001006A (zh)
SG (1) SG11201600379TA (zh)
TW (1) TWI685347B (zh)
WO (1) WO2015021092A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021092A1 (en) * 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
JP6773677B2 (ja) * 2015-03-17 2020-10-21 アローヘッド ファーマシューティカルズ インコーポレイテッド 改善されたジスルフィド含有アルキン連結剤
CN108064313B (zh) 2015-03-17 2021-07-30 箭头药业股份有限公司 用于抑制因子xii的基因表达的组合物和方法
SG11201708602XA (en) 2015-05-29 2017-12-28 Arrowhead Pharmaceuticals Inc Biologically cleavable tetrapeptide linking agents
MX2017014641A (es) 2015-05-29 2018-01-23 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
SI3397651T1 (sl) * 2015-12-29 2020-11-30 Galderma S.A. Oglikovodično zamreževalo
EP3252082A1 (en) * 2016-05-31 2017-12-06 Galderma S.A. Method for deacetylation of biopolymers
PT3623390T (pt) * 2016-05-31 2023-10-27 Galderma Sa Reticulador de hidrato de carbono
IL309955A (en) 2018-04-27 2024-03-01 Arrowhead Pharmaceuticals Inc Integrin-targeting ligands and their uses
CN110240551B (zh) * 2019-06-25 2022-02-11 成都郑源生化科技有限公司 Fmoc-β-Ala-Gly-OH的制备方法
EP4069753A1 (en) 2019-12-02 2022-10-12 Galderma Holding SA High molecular weight esthetic compositions
CN113004515B (zh) * 2021-03-02 2023-02-24 厦门大学附属中山医院 一种仿透明质酸聚氨基酸衍生物、其制备方法及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2161373T3 (es) * 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
CA2250464A1 (en) 1996-03-29 1997-10-09 G.D. Searle & Co. Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
JP2001501600A (ja) * 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
EP0870756B1 (fr) 1997-04-07 2001-11-07 Cfpi Nufarm Procédé de préparation des dinitroanilines 3,4-disubstituées
EP1446418B1 (en) * 2001-10-22 2012-05-23 The Scripps Research Institute Integrin targeting compounds
JP2004261024A (ja) * 2003-02-28 2004-09-24 Japan Science & Technology Agency ペプチド修飾多糖類を用いる遺伝子治療剤
JP2006522158A (ja) * 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド ｉＲＮＡ複合体
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2581869A1 (en) * 2004-11-04 2006-05-18 Raul Andino Syntheses of polyamine conjugates of small interfering rnas (si-rnas) and conjugates formed thereby
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US8017109B2 (en) 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
CA3151965A1 (en) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
ES2562817T3 (es) 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2822161C (en) * 2010-12-29 2018-05-29 Philipp Hadwiger Small molecule conjugates for intracellular delivery of nucleic acids
EP2658579A4 (en) * 2010-12-29 2015-07-22 Arrowhead Res Corp CONJUGATES FOR THE IN VIVO DELIVERY OF POLYNUCLEOTIDES WITH ENZYME-SENSITIVE BINDINGS
US8932572B2 (en) 2011-08-26 2015-01-13 Arrowhead Madison Inc. Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US20150306130A1 (en) 2012-01-27 2015-10-29 Hoffmann-La Roche Inc. Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
MX2014008373A (es) * 2012-01-27 2014-09-26 Hoffmann La Roche Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
WO2015021092A1 (en) * 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Also Published As

Publication number Publication date
EP3030244A1 (en) 2016-06-15
US20170022497A1 (en) 2017-01-26
CN105451743A (zh) 2016-03-30
IL243941B (en) 2019-06-30
TW201601742A (zh) 2016-01-16
CN105451743B (zh) 2019-11-19
AU2014306021A2 (en) 2016-11-24
EP3030244B1 (en) 2021-04-21
CA2919088A1 (en) 2015-02-12
US9487556B2 (en) 2016-11-08
JP6433001B2 (ja) 2018-12-05
KR20160035081A (ko) 2016-03-30
TWI685347B (zh) 2020-02-21
AU2014306021B2 (en) 2018-12-13
EP3030244A4 (en) 2017-06-28
WO2015021092A1 (en) 2015-02-12
AU2014306021A1 (en) 2016-01-28
US20190062748A1 (en) 2019-02-28
IL243941A0 (en) 2016-04-21
SG11201600379TA (en) 2016-02-26
MX2016001006A (es) 2016-04-19
US20150045573A1 (en) 2015-02-12
EA201690051A1 (ru) 2016-06-30
JP2016535058A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
HK1220397A1 (zh) 用於在活體中遞送 觸發子至腫瘤細胞的聚偶聯物
IL244113A0 (en) Selective delivery of substance to cells
HK1206639A1 (zh) 體內製造蛋白質
ZA201507790B (en) Enhanced adoptive cell therapy
EP2971013A4 (en) LIPID NANOPARTICLES FOR TRANSFECTION AND ASSOCIATED METHODS
HK1245834A1 (zh) 一種b細胞用於體內遞送治療劑
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
EP2872036A4 (en) IN VIVO BIOSENSOR
EP2941243A4 (en) SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE
EP2972950A4 (en) SEGMENTATION OF CONTENT DISTRIBUTION
HK1205185A1 (zh) 與褐色脂肪樣細胞相關的方法和組合物
EP2807555A4 (en) PROCESSORS FOR PARA-VIRTUALIZED ASYMMETRIC GRAPHIC PROCESSING UNIT (GPU)
HK1205758A1 (zh) 治療β-聯蛋白相關疾病的有機組合物
SG10201800017RA (en) Cell preparation including fat cell
EP2661489A4 (en) METHOD FOR INCREASING THE DELIVERY OF GEN-TRANSDUCED CELLS
EP2832038A4 (en) INTELLIGENT DISTRIBUTION OF LEGAL INTERCEPTION DATA (LI) IN EMERGENCY CONDITIONS
GB201516123D0 (en) In vivo cell imaging
EP3027739A4 (en) MODIFIED CELLS FOR THE PRODUCTION OF BLOOD CELLS
SG11201502214PA (en) Adipose tissue cells
PL3082858T3 (pl) Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
PL2950663T3 (pl) Sposoby podnoszenia jakości roślin na kiszonki
GB201302197D0 (en) Method of increasing lipid accumulation in pulcherrima cells
GB201304514D0 (en) Cell delivery
EP2994118A4 (en) USE OF LAPPAOL F TO INHIBIT THE GROWTH OF TUMOR CELLS
EP2738248A4 (en) METHOD FOR THE PRODUCTION OF VITRO VASCULARIZED TISSUE